share_log

HC Wainwright & Co. Maintains Buy on Protalix BioTherapeutics, Raises Price Target to $10

Benzinga ·  Oct 31, 2023 19:31

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Protalix BioTherapeutics (AMEX:PLX) with a Buy and raises the price target from $7 to $10.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment